These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 25976961)

  • 1. Pearls and pitfalls in factor inhibitor assays.
    Adcock DM; Favaloro EJ
    Int J Lab Hematol; 2015 May; 37 Suppl 1():52-60. PubMed ID: 25976961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation.
    Favaloro EJ; Bonar R; Duncan E; Earl G; Low J; Aboud M; Just S; Sioufi J; Street A; Marsden K
    Pathology; 2007 Oct; 39(5):504-11. PubMed ID: 17886101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors.
    Favaloro EJ; Bonar R; Kershaw G; Duncan E; Sioufi J; Marsden K
    Semin Thromb Hemost; 2009 Nov; 35(8):794-805. PubMed ID: 20169516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation.
    Favaloro EJ; Bonar R; Duncan E; Earl G; Low J; Aboud M; Just S; Sioufi J; Street A; Marsden K;
    Thromb Haemost; 2006 Jul; 96(1):73-8. PubMed ID: 16807654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen.
    Verbruggen B; van Heerde WL; Laros-van Gorkom BA
    Semin Thromb Hemost; 2009 Nov; 35(8):752-9. PubMed ID: 20169511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External quality assessment of factor VIII inhibitor assays.
    Bonar RA; Favaloro EJ; Marsden K
    Semin Thromb Hemost; 2013 Apr; 39(3):320-6. PubMed ID: 23436565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia.
    Favaloro EJ; Bonar R; Kershaw G; Mohammed S; Duncan E; Marsden K;
    Haemophilia; 2010 Jul; 16(4):662-70. PubMed ID: 20070382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimisation of lupus anticoagulant tests: should test samples always be mixed with normal plasma?
    Pennings MT; De Groot PG; Meijers JC; Huisman A; Derksen RH; Urbanus RT
    Thromb Haemost; 2014 Oct; 112(4):736-42. PubMed ID: 25008787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory testing for factor inhibitors.
    Favaloro EJ; Verbruggen B; Miller CH
    Haemophilia; 2014 May; 20 Suppl 4():94-8. PubMed ID: 24762283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and quantification of factor VIII inhibitors.
    Verbruggen B
    Haemophilia; 2010 May; 16(102):20-4. PubMed ID: 19228204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions.
    Mani H; Hesse C; Stratmann G; Lindhoff-Last E
    Thromb Haemost; 2013 Jan; 109(1):127-36. PubMed ID: 23138190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating laboratory approaches to the identification of lupus anticoagulants: a diagnostic challenge from the RCPA Haematology QAP.
    Bonar R; Favaloro E; Zebeljan D; Rosenfeld D; Kershaw G; Mohammed S; Marsden K; Hertzberg M
    Pathology; 2012 Apr; 44(3):240-7. PubMed ID: 22183703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors.
    Kershaw GW; Chen LS; Jayakodi D; Dunkley SM
    Thromb Res; 2013; 132(6):735-41. PubMed ID: 24119613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center.
    Kershaw G; Jayakodi D; Dunkley S
    Semin Thromb Hemost; 2009 Nov; 35(8):760-8. PubMed ID: 20169512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors.
    Verbruggen B; Giles A; Samis J; Verbeek K; Mensink E; Novákovà I
    Thromb Haemost; 2001 Dec; 86(6):1435-9. PubMed ID: 11776311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. False-positive results in ELISA-based anti FVIII antibody assay may occur with lupus anticoagulant and phospholipid antibodies.
    Sahud M; Zhukov O; Mo K; Popov J; Dlott J
    Haemophilia; 2012 Sep; 18(5):777-81. PubMed ID: 22458845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?
    Pouplard C; Desconclois C; Sobas F; Aillaud MF; Ternisien C; Caron C
    Int J Lab Hematol; 2015 Feb; 37(1):125-32. PubMed ID: 24815078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dilute phospholipid APTT: a sensitive assay for verification of lupus anticoagulants.
    Alving BM; Baldwin PE; Richards RL; Jackson BJ
    Thromb Haemost; 1985 Oct; 54(3):709-12. PubMed ID: 3937268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lupus anticoagulant: case-based external quality assessment.
    van den Besselaar AM; Devreese KM; de Groot PG; Castel A
    J Clin Pathol; 2009 Aug; 62(8):731-4. PubMed ID: 19638545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commonalities and contrasts in recent guidelines for lupus anticoagulant detection.
    Moore GW
    Int J Lab Hematol; 2014 Jun; 36(3):364-73. PubMed ID: 24750683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.